Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, minerals and dietary supplements, feminine hygiene, diabetes care, scar management, and anti-parasite categories under the Good Sense, Sergeant's, Sentry, Zephrex D, PetArmor, and ScarAway brand names.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone353-1709-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.73 billion
Profitability
Miscellaneous
Employees10,600
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable
Perrigo (NYSE:PRGO) Frequently Asked Questions
What is Perrigo's stock symbol?
Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."
How often does Perrigo pay dividends? What is the dividend yield for Perrigo?
Perrigo declared a quarterly dividend on Monday, November 4th. Shareholders of record on Friday, November 29th will be given a dividend of $0.21 per share on Tuesday, December 17th. This represents a $0.84 annualized dividend and a yield of 1.42%. The ex-dividend date of this dividend is Wednesday, November 27th. View Perrigo's Dividend History.
How were Perrigo's earnings last quarter?
Perrigo Company PLC (NYSE:PRGO) posted its quarterly earnings results on Wednesday, November, 6th. The company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.11. The company earned $1.19 billion during the quarter, compared to analyst estimates of $1.20 billion. Perrigo had a return on equity of 9.39% and a net margin of 5.24%. Perrigo's revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.09 EPS. View Perrigo's Earnings History.
When is Perrigo's next earnings date?
What guidance has Perrigo issued on next quarter's earnings?
Perrigo updated its FY 2019
Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.797-4.797 billion, compared to the consensus revenue estimate of $4.77 billion.
What price target have analysts set for PRGO?
6 brokerages have issued 12-month price targets for Perrigo's shares. Their forecasts range from $48.00 to $60.00. On average, they anticipate Perrigo's share price to reach $53.80 in the next year. This suggests that the stock has a possible downside of 8.8%. View Analyst Price Targets for Perrigo.
What is the consensus analysts' recommendation for Perrigo?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Perrigo.
Has Perrigo been receiving favorable news coverage?
News coverage about PRGO stock has trended positive on Monday, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Perrigo earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Perrigo.
Who are some of Perrigo's key competitors?
Some companies that are related to Perrigo include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Perrigo own?
Who are Perrigo's key executives?
Perrigo's management team includes the folowing people:
- Mr. Murray S. Kessler, CEO, Pres & Director (Age 59)
- Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 63)
- Mr. Svend Andersen, Exec. VP & Pres of Consumer Healthcare International (Age 57)
- Mr. Ronald L. Winowiecki, Advisory (Age 53)
Who are Perrigo's major shareholders?
Perrigo's stock is owned by a number of of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.35%), State of Alaska Department of Revenue (0.07%), FTB Advisors Inc. (0.05%), Assenagon Asset Management S.A. (0.05%), Bowling Portfolio Management LLC (0.04%) and Moon Capital Management LLC (0.03%). Company insiders that own Perrigo stock include Geoffrey M Parker, Grainne Quinn, Jeffrey C Smith, Murray S Kessler, Ronald Craig Janish, Ronald Winowiecki, Svend Andersen, Theodore R Samuels II, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.
Which institutional investors are selling Perrigo stock?
PRGO stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Commerzbank Aktiengesellschaft FI, State of Alaska Department of Revenue, Moon Capital Management LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, FTB Advisors Inc. and Nisa Investment Advisors LLC. Company insiders that have sold Perrigo company stock in the last year include Grainne Quinn, Ronald Craig Janish, Ronald Winowiecki and Todd W Kingma. View Insider Buying and Selling for Perrigo.
Which institutional investors are buying Perrigo stock?
PRGO stock was bought by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Assenagon Asset Management S.A., Sciencast Management LP and Contravisory Investment Management Inc.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, Murray S Kessler, Svend Andersen, Theodore R Samuels II, Todd W Kingma and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.
How do I buy shares of Perrigo?
Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Perrigo's stock price today?
One share of PRGO stock can currently be purchased for approximately $59.02.
How big of a company is Perrigo?
Perrigo has a market capitalization of $8.03 billion and generates $4.73 billion in revenue each year. The company earns $131 million in net income (profit) each year or $4.55 on an earnings per share basis. Perrigo employs 10,600 workers across the globe.View Additional Information About Perrigo.
What is Perrigo's official website?
How can I contact Perrigo?
Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]
MarketBeat Community Rating for Perrigo (NYSE PRGO)
MarketBeat's community ratings are surveys of what our community members think about Perrigo and other stocks. Vote "Outperform" if you believe PRGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
